Carlev Tablet 250 mg+25 mg is a combination medication used primarily to manage symptoms of Parkinson's disease and Parkinsonism. Levodopa is a precursor to dopamine, which is deficient in the brains of people with Parkinson's disease. Carbidopa is included to prevent levodopa from being converted into dopamine outside the brain, thus increasing the amount of levodopa that reaches the brain.
This combination medication is used for:
| Brand Name | Carlev |
|---|---|
| Type | Tablet |
| Weight | 250 mg+25 mg |
| Generic | Levodopa + Carbidopa (FC tablet) |
| Manufacturer | Opsonin Pharma Ltd. |
| Available in | English বাংলা |
Levodopa is a dopamine precursor that gets converted into dopamine in the brain. Dopamine is a neurotransmitter that is deficient in Parkinson's disease. Carbidopa inhibits the enzyme aromatic L-amino acid decarboxylase, which prevents the conversion of levodopa to dopamine in the peripheral tissues. This helps increase the amount of levodopa that crosses the blood-brain barrier, enhancing the therapeutic effect while reducing peripheral side effects.
Levodopa + Carbidopa typically starts to improve symptoms within 30 minutes to 1 hour after administration. The full therapeutic effects may take several weeks to achieve as the medication adjusts to the individual’s system.
Levodopa is rapidly absorbed from the gastrointestinal tract, primarily from the duodenum and jejunum. The presence of carbidopa improves the bioavailability of levodopa by inhibiting its conversion to dopamine outside the brain.
Levodopa and its metabolites are primarily eliminated through the urine. Some levodopa is also metabolized in the liver. Carbidopa is excreted mainly through the urine as well.
The dosage of Levodopa + Carbidopa depends on the specific formulation and individual patient needs. Typical dosages for the FC tablet include:
Dosage should be personalized based on individual response and tolerability, and adjustments should be made by a healthcare provider.
Levodopa + Carbidopa FC tablets are administered orally. The tablets should be taken with food to minimize gastrointestinal side effects. The exact dosing schedule should be followed as prescribed by a healthcare provider.
Common side effects include:
Serious side effects may include:
Symptoms of toxicity may include severe nausea, vomiting, confusion, and abnormal movements. Acute overdose can lead to severe dyskinesias, psychotic episodes, and cardiovascular effects. Medical attention should be sought immediately if overdose symptoms occur.
Precautions should be taken in individuals with:
Regular monitoring of blood pressure, heart rate, and other relevant parameters is recommended during treatment.
Levodopa + Carbidopa can interact with various medications, including:
Levodopa + Carbidopa should be used cautiously in patients with:
Drug interactions may occur with:
High-protein meals may interfere with the absorption of levodopa. It is generally recommended to take the medication with a low-protein diet or to space out protein intake throughout the day.
Levodopa + Carbidopa is categorized as a pregnancy category C drug. This means that risk cannot be ruled out. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Levodopa + Carbidopa is excreted in breast milk. It is recommended to either avoid breastfeeding or use the medication only if the benefits outweigh the risks. Consult a healthcare provider for guidance.
Acute overdose may lead to severe nausea, vomiting, cardiovascular effects, and altered mental status. Immediate medical attention is required to manage overdose symptoms.
Levodopa + Carbidopa is contraindicated in individuals with:
Take Levodopa + Carbidopa FC tablets as prescribed by your healthcare provider. Follow the dosage instructions carefully and report any side effects or unusual symptoms promptly. Do not adjust the dose or stop the medication without consulting your healthcare provider.
Store at room temperature, away from moisture and heat. Keep the medication out of reach of children. Do not use beyond the expiration date printed on the package.
The volume of distribution for levodopa is about 2-4 L/kg, which reflects its distribution in the body, including the brain, where it is converted to dopamine.
The half-life of levodopa is approximately 1-2 hours. However, its effects can last longer due to sustained dopamine activity in the brain. The half-life of carbidopa is about 1-2 hours as well.
Levodopa is primarily cleared through the kidneys, with about 70-80% excreted as metabolites in the urine. Carbidopa is also cleared through the kidneys, with a similar excretion pattern.
See in details version Carlev Tablet 250 mg+25 mg also Carlev Tablet 250 mg+25 mg in bangla